GSK

GSK
D

GSK

Arincen73/100B

GSK cash on hand 1985–2026

GSK had 2.98B GBP in cash and short-term investments on 30 September 2026, down 33.0% on a year before. At the end of fiscal year 2025 it had 3.40B GBP.

Last updated 7 Nov 2026 · Next report 3 Feb 2027

Cash on hand

Growth

Fiscal yearPeriod endingCash on handGrowthTotal debtNet cash
Latest quarter30 Sept 20262.98B-32.95%23.86B-20.88B
FY202531 Dec 20253.40B-8.45%17.69B-14.29B
FY202431 Dec 20243.71B-43.78%16.99B-13.27B
FY202331 Dec 20236.61B-16.14%22.97B-16.36B
FY202231 Dec 20227.88B+34.16%20.99B-13.11B
FY202131 Dec 20215.87B-32.57%32.74B-26.87B
FY202031 Dec 20208.71B+37.34%37.11B-28.41B
FY201931 Dec 20196.34B+60.19%40.42B-34.08B
FY201831 Dec 20183.96B+1.20%26.06B-22.11B
FY201731 Dec 20173.91B-21.56%17.09B-13.18B
FY201631 Dec 20164.99B-15.56%18.79B-13.80B
FY201531 Dec 20155.91B+33.99%16.63B-10.73B
FY201431 Dec 20144.41B-21.30%18.78B-14.38B
FY201331 Dec 20135.60B+31.30%18.25B-12.65B
FY201231 Dec 20124.27B-27.69%18.30B-14.04B
FY201131 Dec 20115.90B-6.88%14.90B-9.00B
FY201031 Dec 20106.33B-8.76%15.10B-8.77B
FY200931 Dec 20096.94B+15.43%16.26B-9.32B
FY200831 Dec 20086.01B+32.70%16.19B-10.17B
FY200731 Dec 20074.53B+49.08%10.57B-6.04B
FY200631 Dec 20063.04B-41.92%5.49B-2.45B
FY200531 Dec 20055.23B+31.54%7.36B-2.13B
FY200431 Dec 20043.98B+15.31%5.96B-1.98B
FY200331 Dec 20033.45B+39.76%5.10B-1.65B
FY200231 Dec 20022.47B+6.36%4.64B-2.17B
FY200131 Dec 20012.32B-35.37%4.24B-1.92B
FY200031 Dec 20003.59B+82.71%4.03B-440.00M
FY199931 Dec 19991.97B+4.30%3.51B-1.54B
FY199831 Dec 19981.89B+13.42%3.12B-1.24B
FY199731 Dec 19971.66B+31.70%3.02B-1.36B
FY199631 Dec 19961.26B-0.94%3.25B-1.98B
FY199531 Dec 19951.27B+1,596.37%4.47B-3.20B
FY199430 Jun 199575.10M-97.28%4.18B-4.10B
FY199330 Jun 19942.76B+10.65%672.00M2.09B
FY199230 Jun 19932.50B+42.77%809.00M1.69B
FY199130 Jun 19921.75B-17.85%503.00M1.25B
FY199030 Jun 19912.13B+33.73%1.01B1.12B
FY198930 Jun 19901.59B+23.03%469.00M1.12B
FY198830 Jun 19891.29B+10.41%174.00M1.12B
FY198730 Jun 19881.17B+25.35%264.00M908.00M
FY198630 Jun 1987935.00M+57.94%210.00M725.00M
FY198530 Jun 1986592.00M—116.00M476.00M

Figures in GBP at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Total debt,Free cash flow,Balance sheet

Common questions about GSK's cash

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.